Revance Therapeutics, Inc.

NasdaqGM:RVNC Stock Report

Market Cap: US$382.0m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Revance Therapeutics Management

Management criteria checks 2/4

Revance Therapeutics' CEO is Mark Foley, appointed in Oct 2019, has a tenure of 5.33 years. total yearly compensation is $10.07M, comprised of 7.2% salary and 92.8% bonuses, including company stock and options. directly owns 1.06% of the company’s shares, worth $4.03M. The average tenure of the management team and the board of directors is 5.2 years and 5.6 years respectively.

Key information

Mark Foley

Chief executive officer

US$10.1m

Total compensation

CEO salary percentage7.15%
CEO tenure5.3yrs
CEO ownership1.1%
Management average tenure5.2yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

Seeking Alpha • Sep 26

Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares

Summary I initially downgraded Revance Therapeutics to a "Sell" in June due to financial struggles, competition, and potential cash flow issues by 2025. Revance's merger with Crown Labs at $6.66 per share, an 89% premium, temporarily boosted shares there are concerns surfacing about the deal's stability. The Teoxane dispute over RHA filler sales and marketing efforts could delay or jeopardize the merger, adding uncertainty to Revance's future. Despite potential positives, I maintain my "Sell" rating due to ongoing financial losses, competitive pressures, and merger uncertainties. Read the full article on Seeking Alpha
Seeking Alpha • Jun 20

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

Summary Revance Therapeutics, Inc. operates in the aesthetics and therapeutics markets, selling Daxxify and RHA Collection of dermal fillers in the U.S. Despite positive guidance for 2024, the Revance stock price has fallen by nearly 70% year-to-date, facing financial vulnerability and market skepticism. Wall Street remains skeptical about Revance's business model and forecasts, given it is facing competitive threats and ongoing disputes, making recovery uncertain. The company is in a financially perilous position and faces litigation from AbbVie accusing the company of misappropriating trade secrets. On the one hand, there is a risky contrarian bet with Revance shares down >90% in 15 months, but I am siding with Wall Street - the company faces a fight to survive in the midst of so many issues. Read the full article on Seeking Alpha
Analysis Article • Mar 04

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Those holding Revance Therapeutics, Inc. ( NASDAQ:RVNC ) shares would be relieved that the share price has rebounded...
Seeking Alpha • Feb 29

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Summary Revance Therapeutics, Inc. reported its Q4 and FY 23 earnings yesterday, February 28th - its stock price has been soaring as a result. The company is guiding for ~$280m of revenues in 2024 and narrowing losses - at least on a non-GAAP basis. I gave Revance stock a "sell" rating in my last note on the company at the end of November - I am upgrading my rating to Hold, for 2024. The company still faces major long term obstacles to success in my view, but management remains bullish and there are reasons to be more optimistic for 2024. Read the full article on Seeking Alpha
Analysis Article • Dec 28

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Revance Therapeutics, Inc. ( NASDAQ:RVNC ) shareholders are no doubt pleased to see that the share price has bounced...
Analysis Article • Nov 10

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

The analysts covering Revance Therapeutics, Inc. ( NASDAQ:RVNC ) delivered a dose of negativity to shareholders today...
Analysis Article • Aug 10

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Jun 14

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

When you see that almost half of the companies in the Pharmaceuticals industry in the United States have price-to-sales...
Analysis Article • Apr 17

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Analysis Article • Jan 02

Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

CEO Compensation Analysis

How has Mark Foley's remuneration changed compared to Revance Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$303m

Jun 30 2024n/an/a

-US$304m

Mar 31 2024n/an/a

-US$325m

Dec 31 2023US$10mUS$720k

-US$324m

Sep 30 2023n/an/a

-US$292m

Jun 30 2023n/an/a

-US$337m

Mar 31 2023n/an/a

-US$341m

Dec 31 2022US$7mUS$673k

-US$356m

Sep 30 2022n/an/a

-US$274m

Jun 30 2022n/an/a

-US$263m

Mar 31 2022n/an/a

-US$274m

Dec 31 2021US$7mUS$660k

-US$281m

Sep 30 2021n/an/a

-US$297m

Jun 30 2021n/an/a

-US$303m

Mar 31 2021n/an/a

-US$292m

Dec 31 2020US$9mUS$650k

-US$282m

Sep 30 2020n/an/a

-US$249m

Jun 30 2020n/an/a

-US$209m

Mar 31 2020n/an/a

-US$186m

Dec 31 2019US$18mUS$190k

-US$159m

Sep 30 2019n/an/a

-US$155m

Jun 30 2019n/an/a

-US$146m

Mar 31 2019n/an/a

-US$143m

Dec 31 2018US$243kn/a

-US$143m

Compensation vs Market: Mark's total compensation ($USD10.07M) is above average for companies of similar size in the US market ($USD2.18M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.

CEO

Mark Foley (59 yo)

5.3yrs
Tenure
US$10,068,915
Compensation

Mr. Mark J. Foley serves as Chairman of uLab Systems, Inc. He has been Chief Executive Officer at Revance Therapeutics, Inc. since October 13, 2019 and served as its President since October 13, 2019 until...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Foley
CEO & Director5.3yrsUS$10.07m1.06%
$ 4.0m
Tobin Schilke
CFO & Principal Accounting Officer6.3yrsUS$3.97m0.093%
$ 356.7k
Dwight Moxie
Chief Legal Officer & General Counsel5yrsUS$3.53m0.046%
$ 174.0k
Amie Krause
Chief People Officer1.9yrsno datano data
Conor Gallagher
Head of Medical Affairs & Aesthetics6.8yrsno datano data
David Hollander
Chief Medical Officer of Global Therapeutics Franchise Lead2.1yrsno data0.10%
$ 382.0k
Erica Jordan
Chief Commercial Officerno datano data0.11%
$ 418.1k
5.2yrs
Average Tenure
49yo
Average Age

Experienced Management: RVNC's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mark Foley
CEO & Director7.4yrsUS$10.07m1.06%
$ 4.0m
Angus Russell
Independent Chairman10.9yrsUS$346.03k0.049%
$ 187.5k
Jill Beraud
Independent Director5.7yrsUS$317.53k0.042%
$ 158.7k
Julian Gangolli
Independent Director8.6yrsUS$305.03k0.043%
$ 164.2k
Vladimir Coric
Independent Director1.9yrsUS$421.49k0.020%
$ 75.6k
Olivia Ware
Independent Director3.9yrsUS$295.03k0.030%
$ 115.3k
Carey Kolaja
Independent Director3.9yrsUS$304.18k0.030%
$ 114.9k
Christian Nolet
Independent Director5.6yrsUS$315.03k0.042%
$ 158.7k
5.6yrs
Average Tenure
65yo
Average Age

Experienced Board: RVNC's board of directors are considered experienced (5.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/05 13:05
End of Day Share Price 2025/02/05 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Revance Therapeutics, Inc. is covered by 10 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MarisBMO Capital Markets Equity Research
Louise ChenCantor Fitzgerald & Co.
Donald EllisCitizens JMP Securities, LLC